Merck remain committed after discontinuing Verubecestat study

Ciaran Arthurs's picture
14 February 2018 — Pharmaceutical company Merck have announced the discontinuation of Phase III studies into the effects of Verubecestat, a possible new drug treatment for Alzheimer’s disease. Alzheimer’s disease is the most common form of dementia, the collective term for a range...
Last modified: 
Thursday, 15 February, 2018 - 17:37